Effect of atomoxetine on the cognitive functions in treatment of attention deficit hyperactivity disorder in children with congenital hypothyroidism: a pilot study.

Effect of atomoxetine on the cognitive functions in treatment of attention deficit hyperactivity disorder in children with congenital hypothyroidism: a pilot study.

Int J Neuropsychopharmacol. 2015 Apr 19;

Authors: Yang R, Gao W, Li R, Zhao Z

Abstract
BACKGROUND: With early initiation of T4 supplementation, children with congenital hypothyroidism (CH) still remained some subtle deficits, such as attention and inhibitory control problems. This study was to assess the effects of atomoxetine on cognitive functions in treatment of ADHD symptoms in children with CH.
METHODS: In a 6-month, open-labeled pilot study, 12 children were recruited and received atomoxetine. The measures of efficacy were scores on SNAP-IV and CGI-S. The cognitive functions were evaluated with WISC-R, Digit Span, WCST and Stroop test.
RESULTS: A statistically significant difference was found between the mean CGI-S and SNAP-IV scores before and post-treatment (P<0.01). All the indicators of cognitive functions at endpoint were improved compared with that at baseline. No serious adverse events were reported.
CONCLUSION: Atomoxetine appears to be useful in improving ADHD symptoms, as well as cognitive functions in children with CH. Larger sample size, randomized, double-blind, clinical trial are required to replicate this results.

PMID: 25896257 [PubMed – as supplied by publisher]

via http://ift.tt/1OdKuw2